Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial - Eiermann, W; Pienkowski, T; Crown, J (J Clin Oncol, 2011)